Compound · clinical trials

Keytruda clinical trials

Also listed in trial records as Pembrolizumab (MK-3475), BI1206

Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 302 trials in our USA, Spain, Canada, France, South Korea, Italy, Germany, UK, Australia, Poland, Japan, Israel, China, Belgium, Taiwan, Mexico, Turkey, Brazil, Netherlands, Czechia, Austria, Portugal, Switzerland, Ireland, Denmark, Norway, Singapore, Sweden, India and Egypt registers that name Keytruda as an intervention. Synced 10 Nov 2026

302Current trials

144Recruiting now

151Lead sponsors

30Country registers

Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov registry records · Synced 10 Nov 2026 · Editorial standards

At a glance

Keytruda is named as an intervention in 302 current clinical trials in our USA, Spain, Canada, France, South Korea, Italy, Germany, UK, Australia, Poland, Japan, Israel, China, Belgium, Taiwan, Mexico, Turkey, Brazil, Netherlands, Czechia, Austria, Portugal, Switzerland, Ireland, Denmark, Norway, Singapore, Sweden, India and Egypt registers. 144 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is Merck Sharp & Dohme LLC (59). The most-studied condition is Advanced Solid Tumor.

Patient leaflets for Keytruda

The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.

UK
United Kingdom: Search MHRA Products
Patient information leaflets and SmPCs for UK-licensed products.
US
United States: Search DailyMed
FDA-approved labels, including patient and medication guides.

Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.

Trials by status

Recruiting14448%
Not yet open114%
Active, closed14648%
By invitation10%

Trials by phase

Phase 39230%
Phase 29230%
Phase 1/25920%
Phase 14214%
Phase 2/3103%
Not applicable41%
Phase 421%
Early Phase 110%

Clinical trials of Keytruda

302 trials

Study	Phase	Status	Lead sponsor	Registers
The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials NCT05203172 · Solid Tumors	Phase 4	Recruiting	Pfizer	UK, USA, Germany, France, Spain, Italy, Netherlands, Czechia, Portugal, Turkey, Canada, Brazil, South Korea, Australia, Israel
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587) NCT03486873 · Solid Tumors, Hematologic Malignancies	Phase 3	Recruiting	Merck Sharp & Dohme LLC	Ireland, UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Poland, Switzerland, Austria, Czechia, Norway, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Australia, Israel
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO]) NCT04267848 · ClinicalTrials.gov ↗ · Lung Non-Small Cell Carcinoma, Lung Non-Small Cell Squamous Carcinoma, Lung Non-Squamous Non-Small Cell Carcinoma	Phase 3	Recruiting	National Cancer Institute (NCI)	Norway, Mexico, Israel
Study on the Efficacy of Treatment by Radiotherapy and Pembrolizumab in Newly Diagnosed Metastatic Head & Neck Cancers NCT04747054 · ClinicalTrials.gov ↗ · Squamous Cell Carcinoma of Head and Neck	Phase 3	Recruiting	UNICANCER	France
Pembrolizumab Plus Neoadjuvant Chemotherapy vs. Neoadjuvant Chemoradiotherapy for Locally Advanced ESCC (KEYSTONE-002) NCT04807673 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma	Phase 3	Recruiting	Tianjin Medical University Cancer Institute and Hospital	China
Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets NCT05317858 · Brain Tumor, Non Small Cell Lung Cancer	Phase 3	Recruiting	InSightec	USA, Canada, South Korea
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63) NCT05633654 · Triple Negative Breast Cancer	Phase 3	Recruiting	Gilead Sciences	Ireland, UK, USA, Germany, France, Spain, Italy, Belgium, Brazil, Mexico, Japan, South Korea, Australia, Israel
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab NCT05812807 · Anatomic Stage II Breast Cancer AJCC v8, Early Stage Triple-Negative Breast Carcinoma, Anatomic Stage IIIA Breast Cancer AJCC v8	Phase 3	Recruiting	Alliance for Clinical Trials in Oncology	Canada, Mexico, Israel, Egypt
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer NCT05929768 · Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8	Phase 3	Recruiting	SWOG Cancer Research Network	Mexico, Israel
NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III) NCT06081244 · ClinicalTrials.gov ↗ · Triple Negative Breast Cancer	Phase 3	Recruiting	Women's Cancer Study Group GmbH	Germany
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007) NCT06170788 · Non-small Cell Lung Cancer (NSCLC)	Phase 3	Recruiting	Merck Sharp & Dohme LLC	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Denmark, Poland, Czechia, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia
VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3] NCT06264180 · Advanced Melanoma	Phase 3	Recruiting	Replimune, Inc	UK, USA, Germany, France, Spain, Poland
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010) NCT06312176 · Breast Neoplasms	Phase 3	Recruiting	Merck Sharp & Dohme LLC	Ireland, UK, USA, India, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Poland, Switzerland, Czechia, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Australia, Israel
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004) NCT06345729 · Non-small Cell Lung Cancer	Phase 3	Recruiting	Merck Sharp & Dohme LLC	UK, USA, India, China, Germany, France, Spain, Italy, Netherlands, Poland, Austria, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Australia
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations NCT06357533 · Non-Small Cell Lung Cancer	Phase 3	Recruiting	AstraZeneca	UK, USA, India, China, Germany, Spain, Italy, Belgium, Poland, Austria, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Australia
CARE1 Pragmatic Clinical Trial NCT06364631 · Metastatic Kidney Cancer, Metastatic Kidney Carcinoma	Phase 3	Recruiting	Gustave Roussy, Cancer Campus, Grand Paris	France, Netherlands, Austria, Czechia
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) NCT06393374 · Triple-Negative Breast Cancer	Phase 3	Recruiting	Merck Sharp & Dohme LLC	Ireland, UK, USA, Germany, France, Spain, Italy, Belgium, Sweden, Denmark, Poland, Switzerland, Austria, Czechia, Norway, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Singapore, Australia, Israel
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023] NCT06422143 · Non-small Cell Lung Cancer, NSCLC	Phase 3	Recruiting	Merck Sharp & Dohme LLC	Ireland, UK, USA, China, Germany, France, Spain, Italy, Poland, Austria, Czechia, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Israel
Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas NCT06422806 · ClinicalTrials.gov ↗ · Metastatic Dedifferentiated Liposarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8	Phase 3	Recruiting	National Cancer Institute (NCI)	Canada, Mexico
Personalizing the Use of Pembrolizumab for Patients Who Have a Strong Response in Early Triple Negative Breast Cancer NCT06606730 · ClinicalTrials.gov ↗ · Breast Cancers, Triple Negative Breast Cancer (TNBC)	Phase 3	Recruiting	UNICANCER	France, Belgium
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009) NCT06623422 · Carcinoma, Non-Small-Cell Lung	Phase 3	Recruiting	Merck Sharp & Dohme LLC	Ireland, UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Poland, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Singapore, Australia, Israel
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC NCT06627647 · Non-squamous Non-small Cell Lung Cancer	Phase 3	Recruiting	AstraZeneca	UK, USA, India, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Australia
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer NCT06661720 · ClinicalTrials.gov ↗ · Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma (RCC), Stage II Renal Pelvis Cancer AJCC v8	Phase 3	Recruiting	Alliance for Clinical Trials in Oncology	Mexico
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) NCT06692738 · Non-small Cell Lung Cancer	Phase 3	Recruiting	AstraZeneca	UK, USA, India, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Austria, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Australia
A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases NCT06699212 · Recurrent Head and Neck Squamous Cell Carcinoma	Phase 3	Recruiting	Rakuten Medical, Inc	USA, China, Japan, Taiwan
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer NCT06731478 · Gastric Cancer, Gastroesophageal Junction Cancer	Phase 3	Recruiting	Daiichi Sankyo	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Austria, Czechia, Norway, Portugal, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Australia
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma NCT06743126 · Melanoma, Cutaneous Malignant, Mucosal Melanoma	Phase 3	Recruiting	Immatics US, Inc	UK, USA, Germany, France, Netherlands, Canada, Israel
A Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With IV nqNSCLC NCT06754644 · ClinicalTrials.gov ↗ · NSCLC	Phase 3	Recruiting	Qilu Pharmaceutical Co., Ltd	China
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) NCT06841354 · Triple Negative Breast Neoplasms	Phase 3	Recruiting	Merck Sharp & Dohme LLC	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Denmark, Poland, Czechia, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia, Israel
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer NCT06868277 · Carcinoma, Non-Small Cell Lung	Phase 3	Recruiting	AstraZeneca	Ireland, UK, USA, China, Germany, France, Spain, Italy, Belgium, Switzerland, Portugal, Turkey, Canada, Brazil, Japan, South Korea, Australia, Israel
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4) NCT06875310 · Carcinoma, Non-Small-Cell Lung	Phase 3	Recruiting	Mirati Therapeutics Inc	Ireland, UK, USA, India, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Switzerland, Austria, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia, Israel
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer NCT06899126 · Non-small Cell Lung Cancer	Phase 3	Recruiting	Daiichi Sankyo	UK, USA, India, China, Germany, France, Spain, Italy, Belgium, Poland, Portugal, Turkey, Brazil, Mexico, Japan, South Korea, Taiwan
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29) NCT06952504 · Endometrial Cancer	Phase 3	Recruiting	Merck Sharp & Dohme LLC	Ireland, UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Poland, Austria, Czechia, Norway, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Australia, Israel
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) NCT06966700 · Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms	Phase 3	Recruiting	Merck Sharp & Dohme LLC	UK, USA, India, China, Germany, France, Spain, Italy, Belgium, Sweden, Poland, Czechia, Norway, Portugal, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Singapore, Australia, Israel
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer NCT06989112 · Endometrial Cancer	Phase 3	Recruiting	AstraZeneca	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Poland, Switzerland, Austria, Norway, Canada, Brazil, Japan, South Korea, Taiwan, Australia
Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer NCT07061977 · ClinicalTrials.gov ↗ · Locally Advanced Cervical Adenocarcinoma, Locally Advanced Cervical Adenosquamous Carcinoma, Locally Advanced Cervical Squamous Cell Carcinoma	Phase 3	Recruiting	National Cancer Institute (NCI)	Mexico, Israel
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer NCT07198074 · ClinicalTrials.gov ↗ · Advanced Endometrial Carcinoma, Recurrent Endometrial Carcinoma	Phase 3	Recruiting	National Cancer Institute (NCI)	Mexico
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22) NCT07216703 · Cervical Cancer	Phase 3	Recruiting	Merck Sharp & Dohme LLC	Ireland, UK, USA, India, Germany, France, Spain, Italy, Belgium, Sweden, Denmark, Poland, Austria, Czechia, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Israel
Study Comparing Ivonescimab Alone or Ivonescimab in Combination With Ligufalimab Versus Pembrolizumab for the Treatment of SCCHN NCT07264075 · ClinicalTrials.gov ↗ · Squamous Cell Carcinoma Head and Neck Cancer (HNSCC)	Phase 3	Recruiting	Groupe Oncologie Radiotherapie Tete et Cou	France
A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC) NCT07541170 · Non-small Cell Lung Cancer	Phase 3	Recruiting	Hoffmann-La Roche	Ireland, UK, USA, China, Germany, Spain, Italy, Poland, Portugal, Canada, Brazil, Japan, South Korea
Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309) NCT07566156 · Urothelial Cancer, Urinary Bladder Neoplasms	Phase 3	Recruiting	Astellas Pharma Global Development, Inc	USA, Canada, South Korea, Taiwan
Symbiotic-GYN-18: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Advanced or Recurrent MMR-proficient Endometrial Cancer NCT07578649 · Endometrial Neoplasms, Endometrial Cancer	Phase 3	Recruiting	Pfizer	USA, China, Japan, Taiwan, Australia
An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC NCT07720284 · High-risk Muscle Invasive Urothelial Carcinoma	Phase 3	Recruiting	AstraZeneca	UK, USA, India, China, Germany, France, Spain, Italy, Poland, Canada, Brazil, Japan, South Korea, Taiwan, Australia
Ordastobart (INBRX-106) Add-on to Pembrolizumab in 1L HPV+ PD-L1+ R/M OPSCC (HexAgon-HN) NCT06295731 · Head and Neck Squamous Cell Carcinoma (HNSCC), HPV Oropharyngeal Squamous Cell Carcinoma (HPV+ OPSCC)	Phase 2/3	Recruiting	Inhibrx Biosciences, Inc	UK, USA, China, France, Spain, Italy, Belgium, Poland, South Korea, Taiwan, Australia
Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors NCT06493552 · Muscle-Invasive Bladder Carcinoma, Metastatic Urothelial Carcinoma	Phase 2/3	Recruiting	Vasgene Therapeutics, Inc	USA
Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma. NCT06697301 · Advanced Melanoma	Phase 2/3	Recruiting	Eikon Therapeutics	UK, USA, Germany, France, Spain, Italy, Belgium, Sweden, Denmark, Poland, Switzerland, Austria, Czechia, Norway, Portugal, Canada, South Korea, Australia, Israel
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC NCT06788990 · Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma	Phase 2/3	Recruiting	Bicara Therapeutics	Ireland, UK, USA, India, China, Germany, France, Spain, Italy, Belgium, Poland, Switzerland, Austria, Czechia, Portugal, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Singapore, Australia, Israel
Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma NCT06947928 · Advanced Or Metastatic Merkel Cell Carcinoma	Phase 2/3	Recruiting	TuHURA Biosciences, Inc	USA
A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer. NCT07365319 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer (Squamous or Non Squamous), Stage 4 NSCLC	Phase 2/3	Recruiting	Eikon Therapeutics	USA, Germany, Spain, Belgium, Poland, Austria, Brazil, Mexico, South Korea, Australia
The Drug Rediscovery Protocol (DRUP Trial) NCT02925234 · ClinicalTrials.gov ↗ · Cancer, Tumors, Neoplasm	Phase 2	Recruiting	The Netherlands Cancer Institute	Netherlands
Melanoma Metastasized to the Brain and Steroids NCT03563729 · ClinicalTrials.gov ↗ · Malignant Melanoma	Phase 2	Recruiting	Inge Marie Svane	Denmark
Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma NCT04510636 · ClinicalTrials.gov ↗ · Classical Hodgkin Lymphoma, Relapsed Cancer, Refractory Cancer	Phase 2	Recruiting	University Health Network, Toronto	Canada
Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer NCT04519151 · Ovarian Neoplasms, Carcinoma, Ovarian Epithelial, Neoplasm of Stomach	Phase 2	Recruiting	Sheba Medical Center	Israel
Addition of Pembrolizumab to the Standard of Care Chemotherapy in Patient With SCCOHT NCT04602377 · ClinicalTrials.gov ↗ · Small Cell Ovarian Carcinoma	Phase 2	Recruiting	ARCAGY/ GINECO GROUP	France
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma NCT04671667 · ClinicalTrials.gov ↗ · Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma	Phase 2	Recruiting	National Cancer Institute (NCI)	Mexico
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2 NCT04879329 · Urothelial Carcinoma	Phase 2	Recruiting	Seagen, a wholly owned subsidiary of Pfizer	UK, USA, Spain, Italy, Belgium, Turkey, Canada, Japan, Australia, Israel
DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma NCT04920617 · Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma	Phase 2	Recruiting	ImmunoVaccine Technologies, Inc. (IMV Inc.)	USA, France, Spain, Poland, Canada, Australia
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial NCT05327686 · Metastatic Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8	Phase 2	Recruiting	NRG Oncology	Ireland, Canada, Mexico, Australia, Israel
ATATcH Alternating Treatment Plans for Advanced Cancer NCT05358548 · ClinicalTrials.gov ↗ · Head and Neck Cancer, Lung Cancer	Phase 2	Recruiting	Rutgers, The State University of New Jersey	Israel
Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer NCT05485766 · Triple Negative Breast Neoplasms, Triple Negative Breast Cancer, Breast Neoplasms	Phase 2	Recruiting	Okayama University	Japan
Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery NCT05973864 · ClinicalTrials.gov ↗ · Triple Negative Breast Neoplasms	Phase 2	Recruiting	UNICANCER	France
Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC NCT06078384 · ClinicalTrials.gov ↗ · Triple-negative Breast Cancer	Phase 2	Recruiting	UNICANCER	France, Spain
European Larynx Organ Preservation Study (ELOS) [MK-3475-C44] NCT06137378 · ClinicalTrials.gov ↗ · Squamous Cell Carcinoma of Head and Neck, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma Stage III	Phase 2	Recruiting	University of Leipzig	Germany
Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination With Pembrolizumab, in Unresectable Melanoma Patients NCT06284590 · Melanoma Stage III, Melanoma Stage IV	Phase 2	Recruiting	Philogen S.p.A	USA, Germany, Italy
Carboplatin/Paclitaxel + Pembrolizumab for Locoregionally Advanced Penile Cancer NCT06353906 · ClinicalTrials.gov ↗ · Urologic Neoplasms, Urogenital Neoplasms, Male Urogenital Diseases	Phase 2	Recruiting	The Netherlands Cancer Institute	Netherlands, Belgium
ALPINE: Maintenance Letrozole/Abemaciclib NCT06366347 · ClinicalTrials.gov ↗ · Endometrial Cancer, Recurrent Endometrial Cancer, TP53	Phase 2	Recruiting	Dana-Farber Cancer Institute	Israel
ICI Rechallenge for Advanced NSCLC With Long-Term Response to First-Line ICI NCT06388031 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer	Phase 2	Recruiting	Peking Union Medical College Hospital	China
Preoperative Immunotherapy Combined With Stereotactic Radiation Therapy Boost in the Treatment of HER2-negative Breast Cancer NCT06472583 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 2	Recruiting	Maria Sklodowska-Curie National Research Institute of Oncology	Poland
A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01) NCT06731907 · Non-small Cell Lung Cancer	Phase 2	Recruiting	Merck Sharp & Dohme LLC	USA, Spain, Italy, Poland, Turkey, Taiwan, Israel
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial NCT06770582 · ClinicalTrials.gov ↗ · Non-Muscle Invasive Bladder Urothelial Carcinoma, Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage I Bladder Cancer AJCC v8	Phase 2	Recruiting	National Cancer Institute (NCI)	Canada
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03) NCT06797635 · Breast Neoplasms, Breast Cancer	Phase 2	Recruiting	Merck Sharp & Dohme LLC	USA, Spain, South Korea, Taiwan
Neoadjuvant ADG126 and Pembrolizumab in Locally Advanced Colorectal Cancer NCT06846268 · ClinicalTrials.gov ↗ · Locally Advanced Colorectal Cancer	Phase 2	Recruiting	National University Hospital, Singapore	Singapore
A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012) NCT06961006 · Malignant Melanoma	Phase 2	Recruiting	Merck Sharp & Dohme LLC	USA, Germany, France, Spain, Italy, Poland, Portugal, Canada, Australia, Israel
Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC NCT07098988 · Metastatic Non-Squamous Non-Small Cell Lung Cancer, Adult Solid Tumor	Phase 2	Recruiting	CatalYm GmbH	USA, Germany, Spain, Italy, Poland, Switzerland
IBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer NCT07122687 · ClinicalTrials.gov ↗ · Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer	Phase 2	Recruiting	Innovent Biologics (Suzhou) Co. Ltd	China
Neoadjuvant, SBRT With Intratumoural Pembrolizumab Followed by Neoadjuvant Chemotherapy in Breast Cancer NCT07188246 · ClinicalTrials.gov ↗ · Breast Cancer, Breast Cancer Stage II, Breast Cancer Stage III	Phase 2	Recruiting	London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's	Canada
A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013) NCT07221474 · Squamous Non-small Cell Lung Cancer	Phase 2	Recruiting	Merck Sharp & Dohme LLC	USA, China, France, Spain, Italy, Poland, Turkey, South Korea, Taiwan, Australia
KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J) NCT07252739 · Malignant Neoplasm	Phase 2	Recruiting	Merck Sharp & Dohme LLC	USA, China, Spain, Italy, Netherlands, Turkey, South Korea
Immunotherapy Without Chemotherapy for Advanced Lung Cancer Patients With High PD-L1 Levels NCT07360743 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer (Squamous or Non Squamous)	Phase 2	Recruiting	UNICANCER	France
A Clinical Trial of MK-2010 Alone and With Other Treatments in Participants With Advanced Solid Tumors (MK-2010-002) NCT07793942 · ClinicalTrials.gov ↗ · Malignant Neoplam, Advanced Solid Tumors	Phase 2	Recruiting	Merck Sharp & Dohme LLC	USA, Switzerland, Canada
A Study Evaluating Ficerafusp Alfa (BCA101) QW in Combination With Pembrolizumab vs Alternative Ficerafusp Alfa Dosing in 1L R or M HNSCC NCT07807163 · Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma	Phase 2	Recruiting	Bicara Therapeutics	USA
Neoadjuvant Pembrolizumab and Porustobart in Resectable pMMR/MSS Colon Cancer NCT07808151 · Colon Cancer	Phase 2	Recruiting	Solstice Oncology, Inc	UK, USA, Spain, Italy, Netherlands, Belgium
KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A) NCT04165070 · Carcinoma, Non-Small-Cell Lung	Phase 1/2	Recruiting	Merck Sharp & Dohme LLC	USA, Spain, Italy, Poland, Canada, South Korea, Taiwan, Israel
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) NCT04198766 · Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer	Phase 1/2	Recruiting	Inhibrx Biosciences, Inc	USA, South Korea, Taiwan, Singapore
A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors NCT04219254 · Solid Tumor, Adult	Phase 1/2	Recruiting	BioInvent International AB	USA, Germany, Spain, Sweden, Poland, Israel
Pembrolizumab, Ibrutinib and Rituximab in PCNSL NCT04421560 · ClinicalTrials.gov ↗ · Primary Central Nervous System Lymphoma, Recurrent Cancer, Refractory Cancer	Phase 1/2	Recruiting	Dana-Farber Cancer Institute	Israel
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) NCT04585750 · Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer	Phase 1/2	Recruiting	PMV Pharmaceuticals, Inc	UK, USA, Germany, France, Spain, Italy, South Korea, Singapore, Australia
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 NCT04787042 · Cancer, Solid Tumor, Melanoma	Phase 1/2	Recruiting	Simcha IL-18, Inc	USA
GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors NCT04977453 · Advanced Solid Tumor, Metastatic Solid Tumor, Cervical Cancer	Phase 1/2	Recruiting	GI Innovation, Inc	USA, South Korea
S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors NCT05101070 · ClinicalTrials.gov ↗ · Solid Tumors	Phase 1/2	Recruiting	Shionogi	USA, Japan
A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B) NCT05319730 · Esophageal Squamous Cell Carcinoma	Phase 1/2	Recruiting	Merck Sharp & Dohme LLC	USA, China, Germany, Italy, Switzerland, Norway, Turkey, Brazil, Japan, South Korea, Taiwan, Singapore
A Study in Patients With Advanced Cancers NCT05320588 · ClinicalTrials.gov ↗ · Advanced Cancer, Advanced Solid Tumor, Cancer	Phase 1/2	Recruiting	BiOneCure Therapeutics Inc	USA
To Access the Safety and Effects of Intravenous Administration of VIR-5818 Alone and in Combination With Pembrolizumab in Adult Participants With Locally Advanced or Metastatic HER2-Expressing Cancers NCT05356741 · Locally Advanced or Metastatic HER2-Expressing Cancers	Phase 1/2	Recruiting	Vir Biotechnology, Inc	USA, France, Spain, Portugal, Australia
Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors NCT05394103 · Advanced Cancer, Metastatic Cancer	Phase 1/2	Recruiting	Qurient Co., Ltd	USA, South Korea
ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors NCT05405595 · Advanced/Metastatic Solid Tumors	Phase 1/2	Recruiting	Adagene Inc	USA, China, South Korea
A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma NCT05440708 · Hepatocellular Carcinoma	Phase 1/2	Recruiting	Tvardi Therapeutics, Incorporated	USA
Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study) NCT05482893 · Gastric or Gastroesophageal Junction Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer (BTC)	Phase 1/2	Recruiting	Phanes Therapeutics	USA
A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A) NCT05562830 · Urothelial Carcinoma	Phase 1/2	Recruiting	Merck Sharp & Dohme LLC	UK, USA, Spain, Italy, Netherlands, Denmark, Canada, South Korea, Australia, Israel
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies NCT05669430 · Solid Tumor, Adult, Refractory Cancer, Endometrial Carcinoma (EC)	Phase 1/2	Recruiting	GV20 Therapeutics	USA
Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors NCT05732831 · ClinicalTrials.gov ↗ · Locally Advanced Solid Tumor	Phase 1/2	Recruiting	Tango Therapeutics, Inc	USA, France, Spain
Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors NCT05784688 · Solid Tumor, Biliary Tract Cancer, Head and Neck Squamous Cell Carcinoma	Phase 1/2	Recruiting	TiumBio Co., Ltd	USA, South Korea
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08) NCT05824975 · Advanced Solid Tumor, Metastatic Solid Tumor, Soft Tissue Sarcoma (STS)	Phase 1/2	Recruiting	GI Innovation, Inc	USA, South Korea
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors NCT05970497 · Cancer, Melanoma Stage III, Melanoma Stage IV	Phase 1/2	Recruiting	Krystal Biotech, Inc	USA
Safety and Efficacy of VB10.16 and Pembrolizumab in Patients With Head-Neck Squamous Cell Carcinoma NCT06016920 · HPV Positive Oropharyngeal Squamous Cell Carcinoma, HNSCC	Phase 1/2	Recruiting	Nykode Therapeutics ASA	UK, Germany, France, Spain, Poland, Norway
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis NCT06047379 · ClinicalTrials.gov ↗ · Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult	Phase 1/2	Recruiting	Neonc Technologies, Inc	USA
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies. NCT06137144 · Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma	Phase 1/2	Recruiting	AstraZeneca	UK, USA, China, Germany, France, Spain, Italy, Brazil, Japan, South Korea, Australia
A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs NCT06228326 · Lung Cancer, Non-small Cell, Lung Cancer Metastatic, Solid Tumor, Adult	Phase 1/2	Recruiting	Krystal Biotech, Inc	USA
Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab NCT06249048 · Advanced Solid Tumor	Phase 1/2	Recruiting	Strand Therapeutics Inc	USA, Australia
A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer NCT06385080 · Squamous Cell Carcinoma of Head and Neck	Phase 1/2	Recruiting	Janssen Research & Development, LLC	UK, USA, China, Germany, France, Spain, Poland, Japan, South Korea, Taiwan
A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A) NCT06428409 · Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer	Phase 1/2	Recruiting	Merck Sharp & Dohme LLC	UK, USA, China, Spain, Italy, Switzerland, Turkey, Canada, Japan, South Korea, Taiwan, Australia
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06) NCT06469944 · ClinicalTrials.gov ↗ · Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms	Phase 1/2	Recruiting	Merck Sharp & Dohme LLC	USA, China, Germany, France, Italy, Switzerland, Norway, Brazil, South Korea, Taiwan
Ixovex-1 Single Agent and Combination Therapy NCT06549946 · Solid Tumor, Head and Neck Cancer	Phase 1/2	Recruiting	Psivac Ltd	UK
Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06) NCT06780111 · Esophageal Squamous Cell Carcinoma	Phase 1/2	Recruiting	Merck Sharp & Dohme LLC	USA, China, Germany, France, Italy, Switzerland, Czechia, Norway, Turkey, Brazil, Japan, South Korea, Taiwan, Singapore
Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors NCT06795412 · Advanced Solid Tumors	Phase 1/2	Recruiting	Pyxis Oncology, Inc	USA, France, Spain
ABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors NCT07158918 · Solid Tumors	Phase 1/2	Recruiting	ABL Bio, Inc	USA, South Korea, Australia
KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04) NCT07232602 · Bladder Cancer	Phase 1/2	Recruiting	Merck Sharp & Dohme LLC	UK, USA, France, Spain, Netherlands, South Korea, Israel
A FIH, Phase I/IIa, Trial Assessing Feasibility of Administrations of TIL-based Immunotherapy in Patients With Metastatic CRC and PC NCT07255664 · ClinicalTrials.gov ↗ · Metastatic Colorectal Cancer, Prostate Cancer Metastatic, Prostate Cancer Locally Advanced	Phase 1/2	Recruiting	CuraCell TX AB	Germany
EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors NCT07262619 · Advanced Solid Tumors, MSI-H or dMMR Advanced Solid Tumors, MSI-H/dMMR Gastric Cancer	Phase 1/2	Recruiting	Eikon Therapeutics	USA, Germany, France, Spain, Italy, Belgium, Poland, Austria, Norway, Portugal, South Korea, Singapore, Australia
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors NCT07287917 · Melanoma (Skin Cancer), HER2-low Hormone Receptor Positive Breast Cancer	Phase 1/2	Recruiting	Aminex Therapeutics, Inc	USA
A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors NCT07287995 · Locally Advanced or Metastatic Malignant Solid Tumors	Phase 1/2	Recruiting	Astellas Pharma Global Development, Inc	USA, Japan
Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab NCT07751042 · Advanced Solid Tumor	Phase 1/2	Recruiting	Strand Therapeutics Inc	USA, Australia
A Study of Sigvotatug Vedotin in Advanced Solid Tumors NCT04389632 · Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, HER2 Negative Breast Neoplasms	Phase 1	Recruiting	Seagen, a wholly owned subsidiary of Pfizer	UK, USA, France, Spain, Switzerland, South Korea, Taiwan, Israel
A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001) NCT05067283 · Advanced Solid Tumors	Phase 1	Recruiting	Merck Sharp & Dohme LLC	USA, China, Spain, Italy, Denmark, Poland, Switzerland, Turkey, Canada, Japan, South Korea, Taiwan, Australia, Israel
A Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ATG 037 Monotherapy and Combination Therapy With Pembrolizumab in Patients With Advanced Solid Tumors NCT05205109 · ClinicalTrials.gov ↗ · Locally Advanced or Metastatic Solid Tumors	Phase 1	Recruiting	Antengene Therapeutics Limited	China, Australia
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors NCT05208762 · Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of the Head and Neck, Esophageal Squamous Cell Carcinoma	Phase 1	Recruiting	Seagen, a wholly owned subsidiary of Pfizer	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Canada, Japan
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors NCT05856981 · Solid Tumor, Adult, Metastatic Solid Tumor, Refractory Cancer	Phase 1	Recruiting	Sairopa B.V	USA, Spain, Belgium
Study to Assess the Safety, Tolerability, and Blood Concentration of PMC-309 NCT05957081 · Advanced or Metastatic Solid Tumors	Phase 1	Recruiting	PharmAbcine	Australia
A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors NCT06004245 · Advanced Solid Tumors, Colorectal Cancer	Phase 1	Recruiting	Vividion Therapeutics, Inc	UK, USA, China, France, Spain, Belgium, Denmark, Canada, South Korea, Australia
Dose Escalation and Expansion Study of BH3120 Alone or With Pembrolizuamb in Advanced or Metastatic Solid Tumors NCT06234397 · Advanced or Metastatic Solid Tumors	Phase 1	Recruiting	Hanmi Pharmaceutical Company Limited	USA, South Korea
A Study of MGC026 in Participants With Advanced Solid Tumors NCT06242470 · Advanced Solid Tumor, Advanced Cancer, Metastatic Cancer	Phase 1	Recruiting	MacroGenics	UK, USA, Australia
First In Human Study of CX-801 in Advanced Solid Tumors NCT06462794 · Solid Tumor, Adult	Phase 1	Recruiting	CytomX Therapeutics	USA
An Open-label Dose Escalation/Expansion Trial to Evaluate the Safety and Anti-tumor Activity of TEV-56278 Alone or in Combination With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors NCT06480552 · Advanced Solid Tumors	Phase 1	Recruiting	Teva Branded Pharmaceutical Products R&D LLC	USA, Canada
A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma NCT06600321 · Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma	Phase 1	Recruiting	Alnylam Pharmaceuticals	USA, Italy, South Korea
Dose Escalation and Expansion Study of HM16390 Alone or With Pembrolizumab in Advanced or Metastatic Solid Tumors NCT06724016 · Advanced or Metastatic Solid Tumors	Phase 1	Recruiting	Hanmi Pharmaceutical Company Limited	USA, South Korea
Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer NCT06736379 · ClinicalTrials.gov ↗ · Head and Neck Cancers- Squamous Cell, Head and Neck Cancer, Solid Tumors	Phase 1	Recruiting	VLP Therapeutics	USA
IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC) NCT06940440 · Advanced Or Metastatic Merkel Cell Carcinoma	Phase 1	Recruiting	TuHURA Biosciences, Inc	USA
Study of HC006 in Combination With a PD-1 Inhibitor in Patients With Advanced Solid Tumors NCT06963814 · ClinicalTrials.gov ↗ · Advanced Cancer	Phase 1	Recruiting	HC Biopharma Inc	China
A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors NCT06983743 · Metastatic Solid Tumors	Phase 1	Recruiting	Erasca, Inc	USA, Canada, South Korea
A Study of DS5361b in Participants With Advanced Solid Tumors NCT07182591 · Advanced Solid Tumor	Phase 1	Recruiting	Daiichi Sankyo	USA, Japan
Lutetium (177Lu) DGUL Combined With Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer NCT07244393 · ClinicalTrials.gov ↗ · Metastatic Castration-resistant Prostate Cancer (mCRPC)	Phase 1	Recruiting	Cellbion Co., Ltd	South Korea
A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001) NCT07247110 · Malignant Neoplasm	Phase 1	Recruiting	Merck Sharp & Dohme LLC	USA, Spain, Canada, South Korea, Australia, Israel
Phase 1 Open Label Trial of MST-0312 Alone and in Combination in Subjects With Solid Malignancies NCT07610941 · ClinicalTrials.gov ↗ · Cancer-Neoplasms	Phase 1	Recruiting	Mestag Therapeutics Limited	Spain
Evaluating the Safety and Efficacy of Pembrolizumab Combined With MWA for Advanced NSCLC NCT03769129 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer	Not applicable	Recruiting	Second Affiliated Hospital of Guangzhou Medical University	China
Alpha Radiation Emitters Device (DaRT) in Combination With Check Point Inhibitor for the Treatment of Recurrent Unresectable or mHNSCC NCT05047094 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma, Skin Cancer, Metastatic Head-and-neck Squamous-cell Carcinoma	Not applicable	Recruiting	Alpha Tau Medical LTD	Israel
NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer NCT07178730 · ClinicalTrials.gov ↗ · Breast Cancer, Triple-negative Breast Cancer	Phase 3	Not yet open	Women's Cancer Study Group GmbH	Germany
A Phase II/III Clinical Study to Evaluate HLX07 in Combination With Serplulimab and Chemotherapy Versus Placebo in Combination With Serplulimab or Pembrolizumab and Chemotherapy as First-Line Treatment in Advanced Squamous Non-Small Cell Lung Cancer NCT07318883 · Squamous NSCLC	Phase 2/3	Not yet open	Shanghai Henlius Biotech	China
Lenvatinib and Pembrolizumab in Resectable Mucosal Melanoma NCT04622566 · ClinicalTrials.gov ↗ · Mucosal Melanoma, Neoadjuvant Treatment	Phase 2	Not yet open	Peking University Cancer Hospital & Institute	China
A Prospective Study of Pembrolizumab Combining Chemotherapy in Advanced NSCLC Patients With EGFR Exon 21 Point Mutation. NCT06142617 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer, Immune Checkpoint Inhibitor, EGFR Exon 21 Mutation	Phase 2	Not yet open	Peking Union Medical College Hospital	China
Neoadjuvant Pembrolizumab With a Watch-and-wait Strategy for dMMR/MSI-H Localized Colon Cancer: PREMICES Study. NCT06646445 · ClinicalTrials.gov ↗ · Colon Cancer	Phase 2	Not yet open	GERCOR - Multidisciplinary Oncology Cooperative Group	France
Pembrolizumab Concurrent With and Following Carbon-ion Radiotherapy for Locally Advanced Cervical Adenocarcinoma NCT06805864 · ClinicalTrials.gov ↗ · Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma	Phase 2	Not yet open	Gunma University	Japan
Tracking T-Cell Responses to Evaluate Pembrolizumab Effectiveness in Advanced Non-Small Cell Lung Cancer NCT06951399 · ClinicalTrials.gov ↗ · NSCLC (Advanced Non-small Cell Lung Cancer), NSCLC Stage IV Without EGFR/ALK Mutation, NSCLC Adenocarcinoma	Phase 2	Not yet open	Rabin Medical Center	Israel
Neoadjuvant Immunotherapy and Organ-sparing Treatment in Patients With Stage I-III dMMR Colon Cancer NCT07409844 · ClinicalTrials.gov ↗ · DMMR Colorectal Cancer, Colon Cancer Stage I, Colon Cancer Stage II/III	Phase 2	Not yet open	Ismail Gögenur	Denmark
Enfortumab Vedotin + Pembrolizumab Induction to Spare the Bladder in MIBC NCT07663747 · Urothelial Bladder Cancer	Phase 2	Not yet open	The Netherlands Cancer Institute	Netherlands
Local and Systemic Immune Modulation by Rilvegostomig (AZD2936) in the Treatment of Advanced Gastric Cancer (RILVE Project) NCT07788664 · Advanced Gastric Cancer	Phase 2	Not yet open	Vall d'Hebron Institute of Oncology	Spain
N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer NCT07217496 · Metastatic Urothelial Carcinoma, Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma	Phase 1	Not yet open	ImmunityBio, Inc	USA
Intraperitoneal Immune Checkpoint Inhibitor for Malignant Ascites NCT05745233 · ClinicalTrials.gov ↗ · Malignant Ascites	Not applicable	By invitation	China Medical University Hospital	China, Taiwan
Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung Adenocarcinoma NCT05689671 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer Metastatic	Phase 4	Active, closed	Nikolaj Frost MD	Germany
Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery NCT02506153 · Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Cutaneous Melanoma	Phase 3	Active, closed	National Cancer Institute (NCI)	Ireland, Canada, Mexico, Israel
Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer NCT02954874 · ClinicalTrials.gov ↗ · Breast Carcinoma In Situ, Invasive Breast Carcinoma, Stage I Breast Cancer AJCC v7	Phase 3	Active, closed	National Cancer Institute (NCI)	Norway, Canada, Mexico, Israel, Egypt
Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer NCT03244384 · ClinicalTrials.gov ↗ · Localized Renal Pelvis and Ureter Urothelial Carcinoma, Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis and Ureter Urothelial Carcinoma	Phase 3	Active, closed	National Cancer Institute (NCI)	Norway, Egypt
Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671) NCT03425643 · Non-small Cell Lung Cancer	Phase 3	Active, closed	Merck Sharp & Dohme LLC	Ireland, UK, USA, China, Germany, France, Spain, Italy, Belgium, Poland, Canada, Brazil, Japan, South Korea, Taiwan, Australia, Egypt
Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716) NCT03553836 · Melanoma	Phase 3	Active, closed	Merck Sharp & Dohme LLC	UK, USA, Germany, France, Spain, Italy, Belgium, Poland, Switzerland, Canada, Brazil, Japan, Australia, Israel
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676) NCT03711032 · High-risk Non-muscle Invasive Bladder Cancer	Phase 3	Active, closed	Merck Sharp & Dohme LLC	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Switzerland, Austria, Norway, Portugal, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Australia
Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756) NCT03725059 · Breast Cancer	Phase 3	Active, closed	Merck Sharp & Dohme LLC	Ireland, UK, USA, China, Germany, France, Spain, Belgium, Poland, Portugal, Canada, Brazil, Japan, South Korea, Taiwan, Australia, Israel, Egypt
Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689) NCT03765918 · Head and Neck Neoplasms	Phase 3	Active, closed	Merck Sharp & Dohme LLC	Ireland, UK, USA, Germany, France, Spain, Belgium, Poland, Switzerland, Austria, Portugal, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia, Israel
A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study NCT03768063 · Cancer	Phase 3	Active, closed	Hoffmann-La Roche	USA, Germany, France, Spain, Italy, Belgium, Denmark, Poland, Czechia, Brazil, Mexico, Japan, South Korea, Australia, Israel
Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer NCT03793179 · ClinicalTrials.gov ↗ · Lung Non-Squamous Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8	Phase 3	Active, closed	National Cancer Institute (NCI)	Canada, Mexico, Israel
Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer NCT03914612 · ClinicalTrials.gov ↗ · Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, Endometrial Endometrioid Adenocarcinoma	Phase 3	Active, closed	National Cancer Institute (NCI)	Canada, Mexico, Japan, South Korea, Israel, Egypt
Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303) NCT03924895 · Urinary Bladder Cancer, Muscle-invasive	Phase 3	Active, closed	Merck Sharp & Dohme LLC	Ireland, UK, USA, Germany, France, Spain, Italy, Belgium, Sweden, Denmark, Poland, Turkey, Canada, Mexico, Japan, South Korea, Singapore, Australia, Israel
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer NCT04214067 · Endometrial Endometrioid Adenocarcinoma, Stage I Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Stage II Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8	Phase 3	Active, closed	National Cancer Institute (NCI)	Mexico
Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer NCT04223856 · Urothelial Cancer	Phase 3	Active, closed	Astellas Pharma Global Development, Inc	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Denmark, Poland, Switzerland, Czechia, Turkey, Canada, Mexico, Japan, South Korea, Taiwan, Singapore, Australia, Israel
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992) NCT04241185 · Urinary Bladder Neoplasms	Phase 3	Active, closed	Merck Sharp & Dohme LLC	UK, USA, France, Spain, Italy, Netherlands, Denmark, Poland, Czechia, Portugal, Turkey, Japan, South Korea, Taiwan, Australia, Israel
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012) NCT04380636 · Lung Neoplasms, Carcinoma, Non-Small-Cell Lung	Phase 3	Active, closed	Merck Sharp & Dohme LLC	UK, USA, China, Germany, France, Spain, Italy, Poland, Czechia, Norway, Turkey, Canada, Mexico, Japan, South Korea
Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013) NCT04624204 · Small Cell Lung Cancer	Phase 3	Active, closed	Merck Sharp & Dohme LLC	UK, USA, China, France, Spain, Italy, Belgium, Portugal, Turkey, Canada, Mexico, Japan, South Korea, Australia, Israel
Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053) NCT04634877 · Endometrial Neoplasms	Phase 3	Active, closed	Merck Sharp & Dohme LLC	UK, USA, China, Germany, France, Spain, Italy, Belgium, Sweden, Denmark, Poland, Austria, Czechia, Norway, Turkey, Canada, Mexico, Japan, South Korea, Taiwan, Israel
A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma NCT04657991 · Melanoma	Phase 3	Active, closed	Pfizer	UK, USA, Germany, France, Spain, Italy, Belgium, Poland, Switzerland, Austria, Czechia, Norway, Turkey, Canada, Brazil, Mexico, Israel
Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304) NCT04700124 · Bladder Cancer	Phase 3	Active, closed	Merck Sharp & Dohme LLC	UK, USA, China, Germany, France, Spain, Italy, Poland, Czechia, Portugal, Canada, Japan, South Korea, Taiwan, Singapore, Australia, Israel
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012) NCT04736706 · Carcinoma, Renal Cell	Phase 3	Active, closed	Merck Sharp & Dohme LLC	Ireland, UK, USA, China, Germany, France, Spain, Italy, Sweden, Denmark, Poland, Czechia, Norway, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia, Israel
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49) NCT04895358 · Breast Neoplasms	Phase 3	Active, closed	Merck Sharp & Dohme LLC	Ireland, UK, USA, China, Germany, France, Spain, Italy, Netherlands, Sweden, Poland, Austria, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Australia, Israel
Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65). NCT05116189 · Ovarian Cancer, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms	Phase 3	Active, closed	Merck Sharp & Dohme LLC	Ireland, UK, USA, China, Germany, France, Italy, Netherlands, Belgium, Denmark, Poland, Norway, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Australia, Israel
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15) NCT05173987 · Endometrial Neoplasms	Phase 3	Active, closed	Merck Sharp & Dohme LLC	Ireland, UK, USA, China, Germany, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Poland, Czechia, Norway, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Australia, Israel
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations NCT05215340 · Metastatic Non Small Cell Lung Cancer	Phase 3	Active, closed	Daiichi Sankyo	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Switzerland, Austria, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia, Israel
A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022) NCT05239728 · Carcinoma, Renal Cell	Phase 3	Active, closed	Merck Sharp & Dohme LLC	Ireland, UK, USA, China, Germany, France, Spain, Italy, Netherlands, Sweden, Poland, Czechia, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Australia, Israel
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66) NCT05239741 · ClinicalTrials.gov ↗ · Colorectal Neoplasms	Phase 3	Active, closed	Merck Sharp & Dohme LLC	China
Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma NCT05352672 · Melanoma	Phase 3	Active, closed	Regeneron Pharmaceuticals	Ireland, UK, USA, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Austria, Czechia, Turkey, Canada, Brazil, Mexico, Australia
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer NCT05382286 · Triple Negative Breast Cancer, PD-L1 Positive	Phase 3	Active, closed	Gilead Sciences	UK, USA, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Switzerland, Austria, Czechia, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia, Israel
Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer NCT05502237 · Non-small Cell Lung Cancer	Phase 3	Active, closed	Gilead Sciences	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Austria, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Israel
Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07) NCT05555732 · Metastatic Non Small Cell Lung Cancer	Phase 3	Active, closed	Daiichi Sankyo	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Switzerland, Austria, Czechia, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia, Israel
A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery NCT05608291 · Melanoma	Phase 3	Active, closed	Regeneron Pharmaceuticals	Ireland, UK, USA, Germany, France, Spain, Italy, Belgium, Poland, Czechia, Turkey, Canada, Brazil, Mexico, Australia, Israel
Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46) NCT05609968 · Carcinoma, Non-Small-Cell Lung	Phase 3	Active, closed	Merck Sharp & Dohme LLC	UK, USA, China, Germany, Italy, Poland, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia, Israel
A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03) NCT05629585 · Breast Cancer	Phase 3	Active, closed	AstraZeneca	UK, USA, China, Germany, France, Spain, Italy, Belgium, Sweden, Denmark, Canada, Brazil, Japan, South Korea, Taiwan
Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study NCT05633602 · ClinicalTrials.gov ↗ · Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8	Phase 3	Active, closed	SWOG Cancer Research Network	Mexico, Israel
A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77) NCT05722015 · Metastatic Non-small Cell Lung Cancer	Phase 3	Active, closed	Merck Sharp & Dohme LLC	USA, China, France, Spain, Poland, Turkey, Brazil, Japan, Taiwan
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study NCT05899049 · ClinicalTrials.gov ↗ · Carcinoma, Renal Cell	Phase 3	Active, closed	Merck Sharp & Dohme LLC	China
Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2 NCT05911295 · Urothelial Carcinoma	Phase 3	Active, closed	Seagen, a wholly owned subsidiary of Pfizer	Ireland, UK, USA, China, France, Spain, Italy, Netherlands, Belgium, Sweden, Czechia, Portugal, Canada, Brazil, Japan, South Korea, Taiwan, Singapore, Australia, Israel
A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001) NCT05933577 · Melanoma	Phase 3	Active, closed	Merck Sharp & Dohme LLC	UK, USA, Germany, France, Spain, Italy, Belgium, Sweden, Denmark, Poland, Switzerland, Portugal, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Australia, Israel
A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002) NCT06077760 · Non-small Cell Lung Cancer	Phase 3	Active, closed	Merck Sharp & Dohme LLC	Ireland, USA, Germany, France, Spain, Italy, Belgium, Denmark, Poland, Czechia, Norway, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer NCT06112379 · Breast Cancer	Phase 3	Active, closed	AstraZeneca	UK, USA, India, China, Germany, France, Spain, Italy, Belgium, Poland, Switzerland, Austria, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Singapore, Australia
Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment NCT06151574 · Lung Cancer, Non-squamous, Non-small Cell	Phase 3	Active, closed	Boehringer Ingelheim	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Poland, Austria, Norway, Portugal, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Australia, Israel
A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)-Japan Extension NCT06212752 · ClinicalTrials.gov ↗ · Metastatic Non-small Cell Lung Cancer	Phase 3	Active, closed	Merck Sharp & Dohme LLC	Japan
A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer NCT06311721 · Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer	Phase 3	Active, closed	Amgen	UK, USA, Germany, France, Spain, Italy, Poland, Austria, Turkey, Brazil, Japan, South Korea, Taiwan, Israel
A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer NCT06348199 · Non-small Cell Lung Cancer Stage IV	Phase 3	Active, closed	Samsung Bioepis Co., Ltd	India, Germany, Spain, Turkey, Brazil, Mexico, Japan
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma NCT06556563 · Glioblastoma	Phase 3	Active, closed	NovoCure GmbH	UK, USA, Germany, France, Spain, Italy, Poland, Switzerland, Czechia, Canada, Japan, Israel
A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84) NCT06698042 · Lung Cancer, Non-Small Cell Lung Cancer	Phase 3	Active, closed	Merck Sharp & Dohme LLC	UK, USA, China, Germany, Spain, Poland, Turkey, Japan, South Korea
Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004) NCT06726265 · Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)	Phase 3	Active, closed	Immutep S.A.S	Ireland, UK, USA, India, Germany, Spain, Italy, Belgium, Poland, Austria, Portugal, Turkey, Canada, Brazil, Mexico, Australia
Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC) NCT07162883 · ClinicalTrials.gov ↗ · Carcinoma, Non-Small-Cell Lung	Phase 3	Active, closed	Qilu Pharmaceutical Co., Ltd	India, China, Spain, Poland, Turkey, Israel
Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) NCT05096663 · ClinicalTrials.gov ↗ · Advanced Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8	Phase 2/3	Active, closed	SWOG Cancer Research Network	Mexico, Egypt
IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma NCT05987332 · Metastatic Uveal Melanoma	Phase 2/3	Active, closed	IDEAYA Biosciences	UK, USA, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Switzerland, Canada, Australia, Israel
Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma NCT06082167 · Head and Neck Squamous Cell Carcinoma	Phase 2/3	Active, closed	Exelixis	UK, USA, Germany, France, Spain, Italy, Belgium, Poland, Austria, Czechia, Brazil, Mexico, South Korea, Taiwan, Australia, Israel
Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma NCT02858921 · ClinicalTrials.gov ↗ · Melanoma	Phase 2	Active, closed	Melanoma Institute Australia	Australia
Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma NCT02965716 · Advanced Melanoma, Recurrent Melanoma, Stage III Cutaneous Melanoma AJCC v7	Phase 2	Active, closed	National Cancer Institute (NCI)	Egypt
Phase 2 Study of Pembrolizumab, DPX-Survivac Vaccine and Cyclophosphamide in Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer NCT03029403 · ClinicalTrials.gov ↗ · Advanced Cancer, Ovarian Cancer, Primary Peritoneal Carcinoma	Phase 2	Active, closed	University Health Network, Toronto	Canada
A Randomized Trial of Pembrolizumab & Radiotherapy Versus Radiotherapy in High-Risk Soft Tissue Sarcoma of the Extremity NCT03092323 · ClinicalTrials.gov ↗ · Soft Tissue Sarcoma of the Extremity	Phase 2	Active, closed	Sarcoma Alliance for Research through Collaboration	Italy, Canada, Australia
Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer NCT03137771 · ClinicalTrials.gov ↗ · Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer	Phase 2	Active, closed	NRG Oncology	Canada, Mexico, Israel
Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma NCT03149029 · ClinicalTrials.gov ↗ · Metastatic Melanoma	Phase 2	Active, closed	Massachusetts General Hospital	Israel
Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors NCT03485209 · Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Exocrine Pancreatic Cancer	Phase 2	Active, closed	Seagen, a wholly owned subsidiary of Pfizer	UK, USA, Germany, France, Spain, Italy, Canada
Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease NCT03516279 · ClinicalTrials.gov ↗ · Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Minimal Residual Disease	Phase 2	Active, closed	ECOG-ACRIN Cancer Research Group	Egypt
SBRT +/- Pembrolizumab in Patients With Local-Regionally Recurrent or Second Primary Head and Neck Carcinoma NCT03546582 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma (HNSCC)	Phase 2	Active, closed	RTOG Foundation, Inc	Canada
Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread NCT03547973 · Metastatic Urothelial Cancer	Phase 2	Active, closed	Gilead Sciences	UK, USA, Germany, France, Spain, Italy, Turkey, Mexico, South Korea
A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma NCT03698019 · Acral Lentiginous Melanoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8	Phase 2	Active, closed	National Cancer Institute (NCI)	Mexico
Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab [IIT2018-04-MCARTHUR-NEOHP] NCT03747120 · ClinicalTrials.gov ↗ · HER2-positive Breast Cancer, Breast Cancer	Phase 2	Active, closed	University of Texas Southwestern Medical Center	Mexico
Study of Pembrolizumab in Metastatic HER2-negative Breast Cancer Patients With APOBEC3B Mutation NCT03989089 · ClinicalTrials.gov ↗ · HER2-Negative Breast Cancer	Phase 2	Active, closed	University of Malaya	Singapore
Biomarkers for Neoadjuvant Pembrolizumab in Non-Metastatic Prostate Cancer Positive by 18FDG-PET Scanning NCT04009967 · ClinicalTrials.gov ↗ · Prostate Cancer	Phase 2	Active, closed	CHU de Quebec-Universite Laval	Canada
Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis NCT04074096 · ClinicalTrials.gov ↗ · Malignant Melanoma, BRAF V600 Mutation, Brain Metastases	Phase 2	Active, closed	UNICANCER	France
A Phase II Study of Neoadjuvant Pembrolizumab & Lenvatinib for Resectable Stage III Melanoma NCT04207086 · ClinicalTrials.gov ↗ · Melanoma Stage III	Phase 2	Active, closed	Melanoma Institute Australia	Australia
A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) NCT04225117 · Locally Advanced or Metastatic Malignant Solid Tumors	Phase 2	Active, closed	Astellas Pharma Global Development, Inc	USA, Canada, Japan
Pembrolizumab and Radiotherapy for Patients With NK/T Cell Lymphoma NCT04417166 · ClinicalTrials.gov ↗ · Lymphoma, Extranodal NK-T-Cell	Phase 2	Active, closed	International Extranodal Lymphoma Study Group (IELSG)	China
Cisplatin+Pembrolizumab+RT in Vulvar Cancer NCT04430699 · ClinicalTrials.gov ↗ · Vulvar Cancer, Vulvar Squamous Cell Carcinoma	Phase 2	Active, closed	Massachusetts General Hospital	Israel
Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers NCT04430738 · Colorectal Carcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma	Phase 2	Active, closed	Seagen, a wholly owned subsidiary of Pfizer	USA, Mexico, Japan
Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial NCT04462406 · ClinicalTrials.gov ↗ · Advanced Melanoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8	Phase 2	Active, closed	ECOG-ACRIN Cancer Research Group	Mexico
Study of Pembrolizumab Combination With Chemotherapy in Platinum-sensitive Recurrent Low-grade Serous Ovarian Cancer NCT04575961 · ClinicalTrials.gov ↗ · Ovarian Cancer, Low Grade Serous Carcinoma, Primary Peritoneal Carcinoma	Phase 2	Active, closed	North Eastern German Society of Gynaecological Oncology	Germany
Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03) NCT04675294 · Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma	Phase 2	Active, closed	ALX Oncology Inc	UK, USA, Spain, Netherlands, Belgium, Canada, South Korea, Singapore, Australia
Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04) NCT04675333 · Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma	Phase 2	Active, closed	ALX Oncology Inc	UK, USA, Spain, Netherlands, Belgium, South Korea, Singapore, Australia
OSE2101 Alone or in Combination With Pembrolizumab vs BSC in Patient With Platinum-sensitive Recurrent OC NCT04713514 · ClinicalTrials.gov ↗ · Platinum-sensitive Ovarian Cancer, Relapsed Ovarian Cancer	Phase 2	Active, closed	ARCAGY/ GINECO GROUP	Germany, France, Belgium
Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008). NCT04895722 · Colorectal Cancer	Phase 2	Active, closed	Merck Sharp & Dohme LLC	UK, USA, Germany, France, Spain, Italy, Netherlands, Belgium, Denmark, Poland, Turkey, Canada, South Korea
Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016) NCT04976634 · ClinicalTrials.gov ↗ · Neoplasm Malignant	Phase 2	Active, closed	Merck Sharp & Dohme LLC	USA, France, Spain, Netherlands, Belgium, South Korea, Australia, Israel
Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation or a Homologous Recombination Deficiency (COMPRENDO NCT05033756 · ClinicalTrials.gov ↗ · Malignant Neoplasm of Breast, Breast Cancer	Phase 2	Active, closed	Institut fuer Frauengesundheit	Germany
A Study to Evaluate Pembrolizumab Plus Lenvatinib in PD-L1 Positive TKI Resistant NSCLC Patients NCT05078931 · ClinicalTrials.gov ↗ · NSCLC	Phase 2	Active, closed	Shanghai Chest Hospital	China
Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer NCT05093231 · Pancreatic Cancer	Phase 2	Active, closed	Cambridge University Hospitals NHS Foundation Trust	Australia
Pembrolizumab for Locally Advanced, Irresectable, Non-metastatic dMMR Colorectal Cancers NCT05131919 · ClinicalTrials.gov ↗ · Colorectal Cancer	Phase 2	Active, closed	The Netherlands Cancer Institute	Netherlands
Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) NCT05186974 · Non-small Cell Lung Cancer	Phase 2	Active, closed	Gilead Sciences	UK, USA, Germany, France, Spain, Italy, Canada, South Korea, Taiwan, Australia
A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer NCT05217446 · Metastatic Colorectal Cancer	Phase 2	Active, closed	Pfizer	UK, USA, Germany, France, Spain, Italy, Netherlands, Belgium, Denmark, Poland, Czechia, Norway, Canada, Australia
Docetaxel/Pembrolizumab in Head and Neck Squamous Cell Carcinoma NCT05252429 · ClinicalTrials.gov ↗ · Effect of Drug	Phase 2	Active, closed	Hokkaido University Hospital	Japan
A Study to Evaluate Safety, Efficacy of FF-10832 in Combo With Pembrolizumab in Urothelial & Non-small Cell Lung Cancer NCT05318573 · Advanced Urothelial Carcinoma, Advanced Non Small Cell Lung Cancer	Phase 2	Active, closed	Fujifilm Pharmaceuticals U.S.A., Inc	USA
Neoadjuvant/Adjuvant Pembrolizumab Plus Chemotherapy NCT05383716 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer, Neoadjuvant Therapy, Immune Checkpoint Inhibitor	Phase 2	Active, closed	Peking Union Medical College Hospital	China
Study of Pembrolizumab, Lenvatinib and Chemotherapy Combination in First Line Extensive-stage Small Cell Lung Cancer NCT05384015 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer Extensive Stage	Phase 2	Active, closed	Fundación GECP	Spain
Pembrolizumab in Muscle-invasive Bladder Cancer NCT05406713 · ClinicalTrials.gov ↗ · Muscle Invasive Bladder Carcinoma, Localized Cancer, Urothelial Carcinoma	Phase 2	Active, closed	Matthew Galsky	Mexico
Pembrolizumab and Lenvatinib After Definitive Chemoradiation of Locally Advanced HNSCC NCT05433116 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma	Phase 2	Active, closed	Universität des Saarlandes	Germany
ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer NCT05446298 · ClinicalTrials.gov ↗ · Ovarian Cancer, High Grade Serous Adenocarcinoma of Ovary, Primary Peritoneal Carcinoma	Phase 2	Active, closed	OncoC4, Inc	USA, Egypt
Pembrolizumab in the Treatment of Advanced, Progressive Adrenocortical Carcinoma. NCT05563467 · ClinicalTrials.gov ↗ · Adrenocortical Carcinoma	Phase 2	Active, closed	Maria Sklodowska-Curie National Research Institute of Oncology	Poland
SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors NCT05642780 · Solid Tumor	Phase 2	Active, closed	Klus Pharma Inc	USA, China, Belgium, Poland, Canada, Australia
Assessment of the Efficacy and Safety of Pembrolizumab for Ovarian Squamous Cell Carcinoma NCT05737199 · ClinicalTrials.gov ↗ · Ovarian Squamous Cell Carcinoma	Phase 2	Active, closed	Niigata University Medical & Dental Hospital	Japan
Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors NCT05945823 · Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer, Esophageal Adenocarcinoma, Esophageal Squamous Cell Cancer	Phase 2	Active, closed	Taiho Oncology, Inc	USA, Germany, France, Spain
A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11) NCT06099782 · Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Melanoma	Phase 2	Active, closed	Merck Sharp & Dohme LLC	USA, France, Poland, Turkey, Japan, Australia
Pembrolizumab in Combination With Eftilagimod Alpha and Radiotherapy in Neoadjuvant Treatment of Patients With Soft Tissue Sarcoma - EFTISARC-NEO Trial NCT06128863 · ClinicalTrials.gov ↗ · Neoadjuvant, Immunotherapy, Sarcoma,Soft Tissue	Phase 2	Active, closed	Maria Sklodowska-Curie National Research Institute of Oncology	Poland
Induction Chemo+Immunotherapy in Resectable Epithelioid and Biphasic Pleural Mesothelioma (CHIMERA Study) NCT06155279 · ClinicalTrials.gov ↗ · Pleural Mesothelioma	Phase 2	Active, closed	Istituto Oncologico Veneto IRCCS	Italy
Neo-adjuvant Pembrolizumab as an Alternative Treatment for MMRd Uterine Cancer NCT06180733 · ClinicalTrials.gov ↗ · Endometrial Cancer	Phase 2	Active, closed	University Medical Center Groningen	Netherlands
A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004). NCT06307431 · Renal Cell Carcinoma	Phase 2	Active, closed	Merck Sharp & Dohme LLC	UK, USA, China, Germany, France, Spain, Italy, Poland, Turkey, Canada, South Korea, Taiwan, Australia, Israel
CLOVER - CCR5-targeting Leronlimab With Oral Chemotherapy and VEGF-inhibitor Enriched Regimen NCT06699836 · Metastatic Colorectal Cancer (mCRC)	Phase 2	Active, closed	CytoDyn, Inc	USA
Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01) NCT06788912 · Lung Neoplasm Malignant	Phase 2	Active, closed	Merck Sharp & Dohme LLC	USA, Spain, Italy, Poland, Turkey
Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma NCT03126630 · ClinicalTrials.gov ↗ · Pleural Malignant Mesothelioma	Phase 1/2	Active, closed	National Cancer Institute (NCI)	Canada
Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma NCT03854474 · ClinicalTrials.gov ↗ · Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Stage III Bladder Cancer AJCC v8	Phase 1/2	Active, closed	National Cancer Institute (NCI)	Canada
Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors NCT04041310 · Solid Tumor, Adult	Phase 1/2	Active, closed	Nouscom SRL	UK, USA, Spain, Italy, Belgium, Canada
Glioblastoma Treatment With Irradiation and Olaptesed Pegol (NOX-A12) in MGMT Unmethylated Patients NCT04121455 · ClinicalTrials.gov ↗ · Glioblastoma	Phase 1/2	Active, closed	TME Pharma AG	Germany
Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab NCT04130516 · Solid Tumor, Adult	Phase 1/2	Active, closed	Linnaeus Therapeutics, Inc	USA, Mexico
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC NCT04140526 · Non Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Melanoma	Phase 1/2	Active, closed	OncoC4, Inc	USA, Australia
Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies NCT04561362 · Urinary Bladder Neoplasm, Triple Negative Breast Neoplasms, Hormone Receptor Positive, HER2-negative Neoplasms	Phase 1/2	Active, closed	BicycleTx Limited	UK, USA, France, Spain, Italy, Canada
Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3) NCT04592653 · Advanced Solid Tumor	Phase 1/2	Active, closed	Mural Oncology, Inc	USA, Spain
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) NCT04956640 · Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Endometrial Neoplasms	Phase 1/2	Active, closed	Eli Lilly and Company	USA, France, Canada, Japan, South Korea, Australia
A Beta-only IL-2 ImmunoTherapY Study NCT05086692 · Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma	Phase 1/2	Active, closed	Medicenna Therapeutics, Inc	Ireland, USA, Spain, Switzerland, Portugal, Canada, South Korea, Australia
Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer. NCT05271318 · Platinum-refractory Ovarian Carcinoma, Platinum-resistant Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma	Phase 1/2	Active, closed	TILT Biotherapeutics Ltd	USA
Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors NCT05438420 · Esophageal Cancer, Gastric Cancer, Hepatocellular Cancer	Phase 1/2	Active, closed	Qurient Co., Ltd	USA, South Korea
A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04) NCT05845814 · Metastatic Urothelial Carcinoma, Urothelial Neoplasms	Phase 1/2	Active, closed	Merck Sharp & Dohme LLC	UK, USA, France, Spain, Italy, Netherlands, Canada, South Korea, Taiwan, Australia, Israel
Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors NCT05887492 · Non Small Cell Lung Cancer, Solid Tumors, Adult, Lung Cancer	Phase 1/2	Active, closed	Tango Therapeutics, Inc	USA
A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers. NCT06116136 · MSI-H/dMMR Gastroesophageal-junction Cancer, MSI-H/dMMR Gastric Cancer	Phase 1/2	Active, closed	Servier Bio-Innovation LLC	UK, USA, China, France, Spain, Italy, Belgium, Denmark, Austria, Canada, Brazil, Japan, Australia
T Cells and Pembrolizumab for Recurrent and Newly Diagnosed Glioblastoma NCT06157541 · ClinicalTrials.gov ↗ · Glioblastoma Multiforme, Astrocytoma, Grade IV	Phase 1/2	Active, closed	Queensland Institute of Medical Research	Australia
A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005) NCT06305767 · Bladder Cancer	Phase 1/2	Active, closed	Merck Sharp & Dohme LLC	UK, USA, Germany, France, Spain, Italy, Sweden, Poland, Turkey, Canada, South Korea, Australia
A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04) NCT06483334 · Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma	Phase 1/2	Active, closed	Merck Sharp & Dohme LLC	UK, USA, France, Spain, Italy, Netherlands, Canada, South Korea, Taiwan, Israel
A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations NCT06644768 · Non-small Cell Lung Cancer, Lung Cancer	Phase 1/2	Active, closed	Daiichi Sankyo	USA, China, Brazil, Japan
Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma NCT06784648 · Melanoma Metastatic, Melanoma of Skin, Melanoma BRAF V600E/K Mutated	Phase 1/2	Active, closed	BioInvent International AB	UK, Germany, Spain
Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer NCT02298959 · ClinicalTrials.gov ↗ · Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Colorectal Carcinoma, Metastatic Malignant Solid Neoplasm	Phase 1	Active, closed	National Cancer Institute (NCI)	Canada
Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma NCT02359565 · ClinicalTrials.gov ↗ · Constitutional Mismatch Repair Deficiency Syndrome, Lynch Syndrome, Malignant Glioma	Phase 1	Active, closed	National Cancer Institute (NCI)	Canada
Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors NCT03030378 · ClinicalTrials.gov ↗ · Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm	Phase 1	Active, closed	National Cancer Institute (NCI)	Israel
SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab NCT03161431 · Melanoma Stage III, Melanoma Stage IV	Phase 1	Active, closed	Syntrix Biosystems, Inc	USA
PVX-410 Vaccine Plus Pembrolizumab in HLA-A2+ Metastatic Triple Negative Breast Cancer NCT03362060 · ClinicalTrials.gov ↗ · Triple Negative Breast Cancer, Metastatic Breast Cancer	Phase 1	Active, closed	Massachusetts General Hospital	Israel
NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy NCT03589339 · Radiotherapy, Immunotherapy, Microsatellite Instability-High Solid Malignant Tumour	Phase 1	Active, closed	Nanobiotix	USA
Study of Binimetinib in Combination With Pembrolizumab in Advanced Non-Small Cell Lung Cancer NCT03991819 · ClinicalTrials.gov ↗ · Non-small Cell Carcinoma	Phase 1	Active, closed	University Health Network, Toronto	Canada
DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer NCT04042701 · Breast Cancer, Non-small Cell Lung Carcinoma	Phase 1	Active, closed	Daiichi Sankyo	UK, USA, France, Spain
Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02) NCT04526691 · Advanced or Metastatic NSCLC	Phase 1	Active, closed	Daiichi Sankyo	USA, Spain, Italy, Japan, Taiwan
IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint Inhibitor NCT05359445 · ClinicalTrials.gov ↗ · Refractory Cancer, Recurrent Cancer, Solid Tumor, Adult	Phase 1	Active, closed	Immatics Biotechnologies GmbH	Germany
A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab NCT05378425 · Cancer, Tumor, Solid, Advanced Solid Tumor	Phase 1	Active, closed	Nectin Therapeutics Ltd	USA, Poland, Israel
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers NCT05544929 · Carcinoma, Non-Small-Cell Lung, Cutaneous Melanoma, Carcinoma, Renal Cell	Phase 1	Active, closed	Novartis Pharmaceuticals	USA, China, Germany, France, Spain, Italy, Canada, Japan, South Korea, Taiwan, Singapore
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors NCT05581004 · Locally Advanced or Metastatic Solid Tumors, NSCLC, HNSCC	Phase 1	Active, closed	Genentech, Inc	USA, Spain, Netherlands, Belgium, Canada, South Korea, Taiwan, Australia
A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors NCT05653882 · Solid Tumor, Non Small Cell Lung Cancer, Melanoma	Phase 1	Active, closed	Asher Biotherapeutics, Inc	USA
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors NCT05787587 · Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer	Phase 1	Active, closed	IDEAYA Biosciences	USA
Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001) NCT05853367 · Metastatic Solid Tumors, Advanced Solid Tumors	Phase 1	Active, closed	Merck Sharp & Dohme LLC	USA, Spain, Poland, Switzerland, Canada, Israel
A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma NCT05929235 · Advanced Urothelial Carcinoma, Oral Drug Administration, Open Label	Phase 1	Active, closed	Flare Therapeutics Inc	USA
Oncolytic Adenovirus TILT-123 With Pembrolizumab as Treatment for Refractory Non-Small Cell Lung Cancer NCT06125197 · Lung Cancer	Phase 1	Active, closed	TILT Biotherapeutics Ltd	USA
A Study of DM919 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors NCT06328673 · Advanced Solid Tumor	Phase 1	Active, closed	D2M Biotherapeutics Inc	USA, China
A Phase 1b Trial to Evaluate Safety of MB097 in Combination With Pembrolizumab in Melanoma Patients NCT06540391 · Melanoma	Phase 1	Active, closed	Microbiotica Ltd	UK, France, Spain, Italy
Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) NCT02194738 · ClinicalTrials.gov ↗ · Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIA Lung Cancer AJCC v8	Not applicable	Active, closed	National Cancer Institute (NCI)	Norway, Mexico, Israel
Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies NCT04541108 · Solid Tumor	Early Phase 1	Active, closed	Presage Biosciences	USA

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

Conditions studied with Keytruda

343 conditions

Advanced Solid Tumor13 Breast Cancer12 Non-small Cell Lung Cancer12 Melanoma12 Carcinoma, Non-Small-Cell Lung10 Solid Tumor, Adult8 Solid Tumor7 Advanced Solid Tumors7 Non Small Cell Lung Cancer7 Cancer7 Triple Negative Breast Cancer6 Urothelial Carcinoma6

All 343 conditions

Condition (as registered)	Trials
Advanced Solid Tumor	13
Breast Cancer	12
Non-small Cell Lung Cancer	12
Melanoma	12
Carcinoma, Non-Small-Cell Lung	10
Solid Tumor, Adult	8
Solid Tumor	7
Advanced Solid Tumors	7
Non Small Cell Lung Cancer	7
Cancer	7
Triple Negative Breast Cancer	6
Urothelial Carcinoma	6
Squamous Cell Carcinoma of Head and Neck	6
Triple Negative Breast Neoplasms	6
Advanced Cancer	6
Head and Neck Cancer	6
Head and Neck Squamous Cell Carcinoma	6
Colorectal Cancer	6
Solid Tumors	5
Breast Neoplasms	5
Endometrial Cancer	5
Ovarian Cancer	5
Esophageal Squamous Cell Carcinoma	5
Lung Cancer	5
Metastatic Urothelial Carcinoma	5
Refractory Cancer	5
Endometrial Neoplasms	4
Recurrent Head and Neck Squamous Cell Carcinoma	4
Carcinoma, Renal Cell	4
NSCLC	4
Clinical Stage IV Cutaneous Melanoma AJCC v8	4
Cervical Cancer	4
Non-Small Cell Lung Cancer	4
Metastatic Cancer	4
Advanced Melanoma	4
Metastatic Solid Tumor	4
Melanoma Stage III	4
Advanced or Metastatic Solid Tumors	4
Clinical Stage III Cutaneous Melanoma AJCC v8	3
Carcinoma, Ovarian Epithelial	3
Urothelial Cancer	3
HNSCC	3
Bladder Cancer	3
Locally Advanced Urothelial Carcinoma	3
Colorectal Neoplasms	3
Renal Cell Carcinoma	3
Mucosal Melanoma	3
Melanoma Stage IV	3
Primary Peritoneal Carcinoma	3
Fallopian Tube Cancer	3
Metastatic Melanoma	3
Malignant Melanoma	3
Metastatic Head and Neck Squamous Cell Carcinoma	2
Clear Cell Renal Cell Carcinoma	2
Carcinoma, Non-Small Cell Lung	2
Gastric Cancer	2
Metastatic Non Small Cell Lung Cancer	2
MSI-H/dMMR Gastric Cancer	2
Glioblastoma	2
Colon Cancer	2
Head and Neck Squamous Cell Carcinoma (HNSCC)	2
Urinary Bladder Neoplasms	2
Metastatic Colorectal Cancer	2
Pancreatic Ductal Adenocarcinoma	2
Biliary Tract Cancer	2
Advanced Urothelial Carcinoma	2
Malignant Neoplasm	2
Locally Advanced or Metastatic Solid Tumors	2
Metastatic Non-small Cell Lung Cancer	2
Ovarian Neoplasms	2
Advanced Or Metastatic Merkel Cell Carcinoma	2
Cutaneous Melanoma	2
Metastatic Solid Tumors	2
Locally Advanced or Metastatic Malignant Solid Tumors	2
Esophageal Adenocarcinoma	2
Esophageal Cancer	2
Immunotherapy	2
Prostate Cancer	2
Non Small Cell Lung Cancer (Squamous or Non Squamous)	2
Immune Checkpoint Inhibitor	2
Recurrent Cancer	2
Triple-negative Breast Cancer	2
Lung Non-Squamous Non-Small Cell Carcinoma	2
Anatomic Stage II Breast Cancer AJCC v8	2
Anatomic Stage IIIA Breast Cancer AJCC v8	2
Anatomic Stage IIIB Breast Cancer AJCC v8	2
Endometrial Endometrioid Adenocarcinoma	2
Relapsed Cancer	2
Metastatic Malignant Solid Neoplasm	2
Stage IV Lung Cancer AJCC v8	2
Recurrent Lung Non-Small Cell Carcinoma	2
Hematologic Malignancies	1
Metastatic Renal Cell Carcinoma	1
Stage III Renal Cell Cancer AJCC v8	1
Stage IV Renal Cell Cancer AJCC v8	1
Unresectable Renal Cell Carcinoma	1
Head and Neck Neoplasms	1
Metastatic Cutaneous Melanoma	1
Metastatic Mucosal Melanoma	1
Triple-Negative Breast Cancer	1
Unresectable Solid Tumor	1
Urinary Bladder Cancer, Muscle-invasive	1
Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)	1
Fallopian Tube Neoplasms	1
HER2 Negative Breast Neoplasms	1
Gastroesophageal Junction Cancer	1
Small Cell Lung Cancer	1
Urinary Bladder Neoplasm	1
Hormone Receptor Positive, HER2-negative Neoplasms	1
Hormone Receptor Positive, HER2-low Neoplasms	1
HPV Positive Oropharyngeal Squamous Cell Carcinoma	1
Lung Cancer, Non-squamous, Non-small Cell	1
MSI-H/dMMR Gastroesophageal-junction Cancer	1
Exocrine Pancreatic Cancer	1
Carcinoma, Squamous Cell of Head and Neck	1
High-risk Non-muscle Invasive Bladder Cancer	1
Non-small Cell Lung Cancer (NSCLC)	1
Lung Neoplasms	1
Advanced Malignant Neoplasm	1
Metastatic Urothelial Cancer	1
HR Low-Positive/HER2-Negative Breast Neoplasms	1
Non-squamous Non-small Cell Lung Cancer	1
High-risk Muscle Invasive Urothelial Carcinoma	1
Lymphoma	1
Non-Hodgkin Lymphoma	1
Hodgkin Lymphoma	1
Peripheral T-cell Lymphoma (PTCL)	1
Melanoma Metastatic	1
Melanoma of Skin	1
Melanoma BRAF V600E/K Mutated	1
Melanoma Recurrent	1
Urothelial Neoplasms	1
Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer	1
Squamous Cell Carcinoma of the Head and Neck	1
HPV Oropharyngeal Squamous Cell Carcinoma (HPV+ OPSCC)	1
Non-small Cell Lung Carcinoma	1
PD-L1 Positive	1
Metastatic Uveal Melanoma	1
Melanoma, Cutaneous Malignant	1
Advanced or Metastatic NSCLC	1
Advanced Non Small Cell Lung Cancer	1
Muscle-Invasive Bladder Carcinoma	1
Metastatic Colorectal Cancer (mCRC)	1
Head and Neck Cancers- Squamous Cell	1
Malignant Neoplam	1
Brain Tumor	1
Relapsed Diffuse Large B-cell Lymphoma	1
Refractory Diffuse Large B-cell Lymphoma	1
Diffuse Astrocytoma, IDH-Mutant	1
Glioblastoma, IDH-wildtype	1
Brain Metastases, Adult	1
Locally Advanced or Metastatic HER2-Expressing Cancers	1
Neoplasm Malignant	1
Tumor, Solid	1
Hepatocellular Carcinoma	1
Squamous Non-small Cell Lung Cancer	1
Platinum-refractory Ovarian Carcinoma	1
Platinum-resistant Ovarian Cancer	1
Platinum-Resistant Fallopian Tube Carcinoma	1
Platinum-Resistant Primary Peritoneal Carcinoma	1
MSI-H or dMMR Advanced Solid Tumors	1
MSI-H/dMMR Colorectal Cancer	1
CRC, Colorectal Cancer	1
Gastric or Gastroesophageal Junction Adenocarcinoma	1
Biliary Tract Cancer (BTC)	1
Advanced/Metastatic Solid Tumors	1
High Grade Serous Adenocarcinoma of Ovary	1
Colorectal Carcinoma	1
Gastric Adenocarcinoma	1
GEJ Adenocarcinoma	1
Gastroesophageal Junction	1
Gastroesophageal Adenocarcinoma	1
Esophageal Neoplasms	1
Soft Tissue Sarcoma (STS)	1
Platinum-resistant Ovarian Cancer (PROC)	1
Radiotherapy	1
Microsatellite Instability-High Solid Malignant Tumour	1
Metastasis From Malignant Tumor of Liver	1
Solid Tumors, Adult	1
Lung Adenocarcinoma	1
Endometrial Carcinoma (EC)	1
Squamous Head and Neck Carcinoma	1
Advanced Hepatocellular Carcinoma	1
Metastatic Hepatocellular Carcinoma	1
Lung Cancer, Non-small Cell	1
Lung Cancer Metastatic	1
Lung Neoplasm Malignant	1
Melanoma (Skin Cancer)	1
HER2-low Hormone Receptor Positive Breast Cancer	1
Metastatic Head and Neck Carcinoma	1
Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer	1
Esophageal Squamous Cell Cancer	1
Siewert Type 1 GEJ Cancer	1
Metastatic Non-Squamous Non-Small Cell Lung Cancer	1
Adult Solid Tumor	1
Oncology	1
Hepatocellular Cancer	1
Locally Advanced Solid Tumor	1
Stage 4 NSCLC	1
Oral Drug Administration	1
Open Label	1
Non-small Cell Lung Cancer Stage IV	1
Squamous NSCLC	1
Malignant Ascites	1
Neoadjuvant Treatment	1
Neoadjuvant Therapy	1
Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer	1
Lymphoma, Extranodal NK-T-Cell	1
EGFR Exon 21 Mutation	1
Platinum-sensitive Ovarian Cancer	1
Relapsed Ovarian Cancer	1
Hypopharyngeal Squamous Cell Carcinoma	1
Laryngeal Squamous Cell Carcinoma Stage III	1
Laryngeal Squamous Cell Carcinoma Stage IV	1
Malignant Neoplasm of Breast	1
Prostate Cancer Metastatic	1
Prostate Cancer Locally Advanced	1
Low Grade Serous Carcinoma	1
Non-Small Cell Lung Cancer Metastatic	1
Metastatic Kidney Cancer	1
Metastatic Kidney Carcinoma	1
Squamous Cell Carcinoma Head and Neck Cancer (HNSCC)	1
Small Cell Ovarian Carcinoma	1
BRAF V600 Mutation	1
Brain Metastases	1
Breast Cancers	1
Triple Negative Breast Cancer (TNBC)	1
Advanced Gastric Cancer	1
Small Cell Lung Cancer Extensive Stage	1
Cancer-Neoplasms	1
Pleural Mesothelioma	1
Soft Tissue Sarcoma of the Extremity	1
Urothelial Bladder Cancer	1
Tumors	1
Neoplasm	1
Neoplasia	1
Urologic Neoplasms	1
Urogenital Neoplasms	1
Male Urogenital Diseases	1
Penile Cancer	1
DMMR Colorectal Cancer	1
Colon Cancer Stage I	1
Colon Cancer Stage II/III	1
Pembrolizumab	1
Adrenocortical Carcinoma	1
Neoadjuvant	1
Sarcoma,Soft Tissue	1
Radiation Therapy	1
Lung Non-Small Cell Carcinoma	1
Lung Non-Small Cell Squamous Carcinoma	1
Stage II Lung Cancer AJCC v8	1
Breast Carcinoma In Situ	1
Invasive Breast Carcinoma	1
Stage I Breast Cancer AJCC v7	1
Stage II Breast Cancer AJCC v6 and v7	1
Stage IB Lung Non-Small Cell Carcinoma AJCC v7	1
Stage II Lung Non-Small Cell Cancer AJCC v7	1
Stage IIA Lung Cancer AJCC v8	1
Stage IIB Lung Cancer AJCC v8	1
Localized Renal Pelvis and Ureter Urothelial Carcinoma	1
Locally Advanced Bladder Urothelial Carcinoma	1
Locally Advanced Renal Pelvis and Ureter Urothelial Carcinoma	1
Locally Advanced Ureter Urothelial Carcinoma	1
Non-Muscle Invasive Bladder Urothelial Carcinoma	1
Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma	1
Stage I Bladder Cancer AJCC v8	1
Metastatic Dedifferentiated Liposarcoma	1
Metastatic Undifferentiated Pleomorphic Sarcoma	1
Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8	1
Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8	1
Constitutional Mismatch Repair Deficiency Syndrome	1
Lynch Syndrome	1
Malignant Glioma	1
Recurrent Brain Neoplasm	1
Non-small Cell Carcinoma	1
Early Stage Triple-Negative Breast Carcinoma	1
Endometrial Clear Cell Adenocarcinoma	1
Endometrial Dedifferentiated Carcinoma	1
Endometrial Mixed Cell Adenocarcinoma	1
Classical Hodgkin Lymphoma	1
Breast Cancer Stage II	1
Breast Cancer Stage III	1
Breast Cancer Invasive	1
Pleural Malignant Mesothelioma	1
Stage III Bladder Cancer AJCC v8	1
Stage IV Bladder Cancer AJCC v8	1
Metastatic Colorectal Carcinoma	1
Recurrent Non-Small Cell Lung Carcinoma	1
Stage IV Non-Small Cell Lung Cancer	1
Stage IIIB Lung Cancer AJCC v8	1
Stage IIIC Lung Cancer AJCC v8	1
HER2-positive Breast Cancer	1
Anatomic Stage I Breast Cancer AJCC v8	1
Muscle Invasive Bladder Carcinoma	1
Localized Cancer	1
Renal Cell Carcinoma (RCC)	1
Stage II Renal Pelvis Cancer AJCC v8	1
Stage III Renal Pelvis Cancer AJCC v8	1
Stage I Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8	1
Stage II Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8	1
Locally Advanced Cervical Adenocarcinoma	1
Locally Advanced Cervical Adenosquamous Carcinoma	1
Locally Advanced Cervical Squamous Cell Carcinoma	1
Stage IIIA Cervical Cancer FIGO 2018	1
Recurrent Hypopharyngeal Squamous Cell Carcinoma	1
Recurrent Laryngeal Squamous Cell Carcinoma	1
Recurrent Oral Cavity Squamous Cell Carcinoma	1
Acral Lentiginous Melanoma	1
Advanced Lung Non-Small Cell Carcinoma	1
Stage III Lung Cancer AJCC v8	1
Stage IIIA Lung Cancer AJCC v8	1
Advanced Endometrial Carcinoma	1
Recurrent Endometrial Carcinoma	1
Melanoma of Unknown Primary	1
Cervical Adenocarcinoma	1
Cervical Adenosquamous Carcinoma	1
Ovarian Squamous Cell Carcinoma	1
Effect of Drug	1
Metastatic Castration-resistant Prostate Cancer (mCRPC)	1
HER2-Negative Breast Cancer	1
Locally Advanced Colorectal Cancer	1
Glioblastoma Multiforme	1
Astrocytoma, Grade IV	1
Pancreatic Cancer	1
Primary Central Nervous System Lymphoma	1
Metastatic Breast Cancer	1
Skin Cancer	1
Metastatic Head-and-neck Squamous-cell Carcinoma	1
Neoplasm of Stomach	1
Ovarian Diseases	1
Unresectable Malignant Solid Neoplasm	1
Recurrent Endometrial Cancer	1
TP53	1
Vulvar Cancer	1
Vulvar Squamous Cell Carcinoma	1
NSCLC (Advanced Non-small Cell Lung Cancer)	1
NSCLC Stage IV Without EGFR/ALK Mutation	1
NSCLC Adenocarcinoma	1
Recurrent Melanoma	1
Stage III Cutaneous Melanoma AJCC v7	1
Stage IIIA Cutaneous Melanoma AJCC v7	1
Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive	1
Minimal Residual Disease	1

By country register

Register	Trials	Recruiting
Clinical trials in USA	185	98
Clinical trials in Spain	125	58
Clinical trials in Canada	110	45
Clinical trials in France	107	51
Clinical trials in South Korea	106	59
Clinical trials in Italy	99	46
Clinical trials in Germany	98	44
Clinical trials in UK	95	42
Clinical trials in Australia	94	44
Clinical trials in Poland	84	37
Clinical trials in Japan	84	37
Clinical trials in Israel	84	36
Clinical trials in China	80	41
Clinical trials in Belgium	67	29
Clinical trials in Taiwan	67	34
Clinical trials in Mexico	62	22
Clinical trials in Turkey	61	26
Clinical trials in Brazil	61	29
Clinical trials in Netherlands	48	22
Clinical trials in Czechia	34	15
Clinical trials in Austria	32	16
Clinical trials in Portugal	32	16
Clinical trials in Switzerland	30	16
Clinical trials in Ireland	29	13
Clinical trials in Denmark	28	13
Clinical trials in Norway	26	13
Clinical trials in Singapore	25	13
Clinical trials in Sweden	21	10
Clinical trials in India	15	11
Clinical trials in Egypt	10	1

A trial with sites in more than one country appears in each of those registers.

Related compounds

Questions about Keytruda trials

How many clinical trials are testing Keytruda?

302 current trials in our USA, Spain, Canada, France, South Korea, Italy, Germany, UK, Australia, Poland, Japan, Israel, China, Belgium, Taiwan, Mexico, Turkey, Brazil, Netherlands, Czechia, Austria, Portugal, Switzerland, Ireland, Denmark, Norway, Singapore, Sweden, India and Egypt registers name Keytruda (also registered as Pembrolizumab (MK-3475)) as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.

Are Keytruda trials recruiting patients?

Yes. 144 of the 302 trials are recruiting: 98 with sites in USA, 58 with sites in Spain, 45 with sites in Canada, 51 with sites in France, 59 with sites in South Korea, 46 with sites in Italy, 44 with sites in Germany, 42 with sites in UK, 44 with sites in Australia, 37 with sites in Poland, 37 with sites in Japan, 36 with sites in Israel, 41 with sites in China, 29 with sites in Belgium, 34 with sites in Taiwan, 22 with sites in Mexico, 26 with sites in Turkey, 29 with sites in Brazil, 22 with sites in Netherlands, 15 with sites in Czechia, 16 with sites in Austria, 16 with sites in Portugal, 16 with sites in Switzerland, 13 with sites in Ireland, 13 with sites in Denmark, 13 with sites in Norway, 13 with sites in Singapore, 10 with sites in Sweden, 11 with sites in India and 1 with sites in Egypt. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Who sponsors Keytruda clinical trials?

Merck Sharp & Dohme LLC (59), National Cancer Institute (NCI) (20), AstraZeneca (9) and Daiichi Sankyo (8), among 151 lead sponsors in total. The number in brackets is how many trials each organisation leads.

Are there Keytruda clinical trials in Ireland?

Yes. 29 trials in our Ireland register (ClinicalTrials.gov). Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Keytruda works or whether it is effective, and it is not medical advice.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Keytruda works or whether it is effective. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Keytruda (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.